Acute lymphoblastic leukemia (ALL) is relatively rare overall but is the single most common cancer in children. About 6,100 new cases are expected in the United States in 2025, and the average person’s chance of ever developing it remains low. Still, the disease is far more common in certain age groups, ethnicities, and sexes than others.
Overall Incidence in the US
Roughly 6,000 Americans are diagnosed with ALL each year, split unevenly between about 3,400 males and 2,600 females. To put that in perspective, ALL accounts for a small fraction of the nearly two million total cancer diagnoses in the US annually. An estimated 1,400 people die from the disease each year, giving it a death rate of about 0.4 per 100,000 people.
Why ALL Is Mainly a Childhood Disease
ALL stands out among cancers because it peaks in very young children. It represents 20% of all cancers diagnosed in people under age 20, translating to more than 3,000 new pediatric cases per year. Rates are highest in children ages 1 to 4, where the incidence reaches about 75 per million. After early childhood, rates drop significantly through adolescence and young adulthood, then rise modestly again in older adults.
This age pattern matters because it shapes survival. Children under 15 have cure rates exceeding 85%. Adults fare considerably worse. The biology of the disease shifts with age: the genetic subtypes that dominate in children tend to respond well to treatment, while the subtypes more common in adults are harder to treat. For example, one particularly aggressive genetic subtype accounts for only 2% to 5% of childhood ALL but rises to at least 25% of adult cases.
Differences by Sex
Boys and men develop ALL more often than girls and women at every age. Among children, the incidence rate is about 38 per million in males compared to roughly 30 per million in females, a ratio of nearly 1.3 to 1. The reasons aren’t fully understood, but this male predominance is one of the most consistent patterns in ALL epidemiology.
Differences by Race and Ethnicity
ALL rates vary substantially across racial and ethnic groups in the US. Hispanic and Latino individuals have the highest incidence across all age groups, and this gap is especially pronounced in children. Among young adults ages 15 to 39, Hispanic/Latino individuals are diagnosed at roughly twice the rate of non-Hispanic white individuals and about three times the rate of Black individuals.
The pattern holds in older adults too. For those 40 and older, Hispanic/Latino individuals have an incidence rate of about 1.76 per 100,000, compared to 0.97 for non-Hispanic white individuals and 0.77 for Black individuals. American Indian and Alaska Native populations fall in the middle, while Asian and Pacific Islander populations have rates similar to or slightly below those of non-Hispanic white individuals. Black individuals consistently have the lowest ALL rates of any group, a disparity researchers have documented across nearly every ALL subtype.
B-Cell vs. T-Cell ALL
ALL comes in two main forms based on which type of immune cell becomes cancerous. B-cell ALL is by far the more common type, making up 85% to 90% of all cases. T-cell ALL accounts for the remaining 10% to 15%, though the exact proportion varies by age, race, and ethnicity. This distinction matters for treatment planning, since the two types can behave differently and may require different therapy approaches.
How Survival Has Changed
ALL was once almost uniformly fatal. Today, the picture is dramatically different for children: more than 85% are cured. This improvement, driven by decades of clinical trials refining chemotherapy combinations, is one of the major success stories in cancer treatment. For adults, outcomes have improved too, but cure rates remain significantly lower. Age at diagnosis is the single strongest predictor of how well someone will do, with younger patients consistently faring better regardless of other factors.
The roughly 1,400 annual deaths from ALL in the US reflect this split. Most children survive, so the majority of deaths occur in adolescents, young adults, and older adults, where the disease is less common but more difficult to treat.